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Depression has been associated with drug consumption, including heavy or problematic
cannabis use. According to an animal model of depression and substance use disorder
comorbidity, we combined the olfactory bulbectomy (OBX) model of depression with
intravenous drug self-administration procedure to verify whether depressive-like rats
displayed altered voluntary intake of the CB1 receptor agonist WIN55,212-2 (WIN,
12.5μg/kg/infusion). To this aim, olfactory-bulbectomized (OBX) and sham-operated
(SHAM) Lister Hooded rats were allowed to self-administer WIN by lever-pressing under
a continuous [fixed ratio 1 (FR-1)] schedule of reinforcement in 2 h daily sessions. Data
showed that both OBX and SHAM rats developed stable WIN intake; yet, responses in
OBX were constantly higher than in SHAM rats soon after the first week of training.
In addition, OBX rats took significantly longer to extinguish the drug-seeking behavior
after vehicle substitution. Acute pre-treatment with serotonin 5HT1B receptor agonist,
CGS-12066B (2.5–10mg/kg), did not significantly modify WIN intake in OBX and SHAM
Lister Hooded rats. Furthermore, acute pre-treatment with CGS-12066B (10 and 15mg/kg)
did not alter responses in parallel groups of OBX and SHAM Sprague Dawley rats
self-administering methamphetamine under higher (FR-2) reinforcement schedule with
nose-poking as operandum. Finally, dopamine levels in the nucleus accumbens (NAc) of
OBX rats did not increase in response to a WIN challenge, as in SHAM rats, indicating
a dopaminergic dysfunction in bulbectomized rats. Altogether, our findings suggest that
a depressive-like state may alter cannabinoid CB1 receptor agonist-induced brain reward
function and that a dopaminergic rather than a 5-HT1B mechanism is likely to underlie
enhanced WIN self-administration in OBX rats.
Keywords: WIN55212-2, cannabinoid, methamphetamine, olfactory bulbectomy, depression, drug dependence,
serotonin, dopamine
INTRODUCTION
Many psychiatric disorders including depression, schizophre-
nia, and anxiety are frequently associated to drug addiction
(Langas et al., 2010; Testa et al., 2013). Recently, clinical asso-
ciations between depression and marijuana smoking have been
reported (Horwood et al., 2012; Lev-Ran et al., 2013). Yet,
whether cannabis abuse in depressed patients antedates the dis-
order onset or is a consequence of its course is still to be
determined. Several hypotheses have been offered to explain
the high rates of marihuana smoking in people with depres-
sion including genetic factors, environmental influences, and
self-medication. Recently, a genetically conditioned hypersensi-
tivity to elicit cannabis dependence was evaluated in a depressive
population, and although the outcome was not fully conclusive
authors suggested that the links between cannabis use and depres-
sive symptoms are conditional on the individual’s genetic makeup
(Otten and Engels, 2013). Social difficulties such as limited eco-
nomical resources, impaired interpersonal skills, social isolation,
or stressful events may also trigger both depression and cannabis
abuse (Baker et al., 2010). On the other hand, cannabis use has
been proposed to serve as a self-medication in depressed patients
(Degenhardt et al., 2003), although some studies excluded that
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subjects with prior depression experience symptom relief after
smoking cannabis (Arendt et al., 2007).
The self-medication theory was developed on the basis
of the monoaminergic hypothesis of depression, according to
which depression is associated with a reduced monoamin-
ergic transmission, in particular noradrenaline and serotonin
(5-HT) (Rotenberg, 1994; Prins et al., 2011). In fact, symp-
toms related to monoaminergic deficits (as in depression) may
be relieved by a variety of abused drugs (Khantzian, 1985;
Hall and Queener, 2007; Becker et al., 2012; Holma et al.,
2013). Accordingly, stimulant-dependent patients with depres-
sive disorders reduce their abuse of stimulants when treated
with antidepressants to a greater extent than non-depressed
(stimulant-dependent) individuals (Markou et al., 1998; Wohl
and Ades, 2009). Similar to other abused drugs, cannabis induces
release of dopamine (DA) in the mesolimbic reward pathway
(Oleson and Cheer, 2012), thus elevating mood and improv-
ing wellbeing. However, it also significantly affects bioavailability
of serotonin. Notably, genetic deletion of the cannabinoid
CB1 receptor reduces the functionality of the brain sero-
tonin system (Mato et al., 2007), while chronic CB1 receptor
antagonism induces a depression-like phenotype (Beyer et al.,
2010).
Majority of available studies aimed at investigating the role
of endocannabinoid system in animal models of depression
reported a decreased activity of the endocannabinoid system
(Micale et al., 2013a,b). Pharmacological and genetic blockade of
cannabinoid CB1 receptors result in symptoms that mimic those
seen in depression (Ashton and Moore, 2011). In keeping with
this, stimulation of CB1 receptors exerts an antidepressant-like
effect similar to that induced by the antidepressants desipramine
and fluoxetine in the rat forced-swim test (Hill and Gorzalka,
2005) and the olfactory bulbectomy (OBX) rat model of depres-
sion (Rodriguez-Gaztelumendi et al., 2009), respectively. These
antidepressant effects are antagonized by administration of CB1
receptor antagonists leading back to depression-like phenotypes
(Hill and Gorzalka, 2005). All these and other preclinical evi-
dence strengthen the involvement of the endocannabinoid system
in depressive-like states. However, no data are available on the vol-
untary consumption of cannabinoid receptor agonists in animal
models of depression.
The multi-faceted effects of 5-HT are mediated by at least
14 receptor subtypes (Hoyer et al., 1994). Among them, the
5-HT1B receptor subtype has recently attracted scientific atten-
tion for its potential role in modulating addictive behaviors
(Pentkowski et al., 2012; Neisewander et al., 2013). Serotonin 5-
HT1B receptors are widely distributed in the brain where function
as both autoreceptors and heteroreceptors, that mediate release
of serotonin and other neurotransmitters (Barnes and Sharp,
1999; Moret and Briley, 2000; Pytliak et al., 2011; Cai et al.,
2013). A number of human and animal studies demonstrated a
causal link between altered 5-HT1B receptor activity and devel-
opment of neuropsychiatric conditions, including depression and
drug addiction. For example, lower functioning of 5-HT1B recep-
tors was found in patients suffering major depressive disorders
(Murrough et al., 2011), while a polymorphism at the 5-HT1B
receptor gene (HTR1B) was reported to be associated significantly
with alcoholism (Lappalainen et al., 1998). In animal models of
drug addiction, stimulation of the 5-HT1B receptor was shown
to induce antidepressant effects (Tatarczynska et al., 2004) and to
decrease the number of behavioral responses for alcohol (Grant
et al., 1997; Maurel et al., 1999; Tomkins and O’Neill, 2000),
d-amphetamine (Fletcher and Korth, 1999), intracranial self-
stimulation (Hayes et al., 2009) and the positive reinforcing effects
of cocaine in rats (Harrison et al., 1999). More importantly,
administration of the 5-HT1B receptor agonist CGS-12066B
into the nucleus accumbens (NAc) core was shown to decrease
operant responses for ethanol but not sucrose solution in rats
(Czachowski, 2005) indicating a selective effect of this compound
on drug-induced responses. However, systemic administration
of CGS-12066B did not reduce cocaine self-administration
in rats (Parsons et al., 1996), which implies a certain drug
selectivity of this compound in attenuating self-administration
behavior.
The main aim of this study was to investigate the intravenous
self-administration of the CB1 receptor agonist WIN55-212,2,
(WIN), using lever-pressing as operandum under a continuous
[fixed ratio 1 (FR-1)] schedule of reinforcement, in a well-
established rat model of depression, the bilateral OBX. Given
the significant differences observed in WIN self-administration
between OBX and SHAM rats, we decided to perform pilot
experiments in an attempt to shed some light on possible under-
lying mechanisms. Therefore, since the 5-HT1B receptor has been
recently involved in the modulation of both depression and drug
intake, we tested the effect of the 5-HT1B agonist CGS-12066B
(CGS) on WIN self-administration in OBX and sham-operated
(SHAM) Lister Hooded rats displaying depressive-like pheno-
types. To further investigate the role of 5-HT1B receptor in drug-
taking behavior and verify its effect on the self-administration
of a different drug, in different strains of rats and under dis-
similar experimental conditions, we tested the CGS compound
in OBX and SHAM Sprague Dawley rats self-administering
methamphetamine (METH) as previously reported (Kucerova
et al., 2012). CGS was chosen because of its high selectiv-
ity to 5-HT1B receptors (Neale et al., 1987) and its reducing
effects on amphetamine (Fletcher and Korth, 1999) and alco-
hol self-administration (Tomkins and O’Neill, 2000; Czachowski,
2005). Finally, since cannabinoid self-administration was shown
to be associated to an increased DA transmission in the shell
of the NAc (Fadda et al., 2006), we used the in vivo micro-
dialysis technique to test whether OBX and SHAM rats dis-
played similar increase in DA levels within the NAc shell in
response to a challenge of WIN at a dose (0.3mg/kg) mimick-
ing daily mean amount of the drug typically self-administer by
trained rats.
MATERIALS AND METHODS
ANIMALS
Adult male Lister Hooded rats weighting 250–270 g at the
beginning of the experiment (9 weeks old) were purchased
from Harlan-Nossan (Italy) and housed four per cage at the
Animal Facility of the Department of Biomedical Sciences,
University of Cagliari, Italy. Rats were provided with free access
to water and food and maintained on a reversed 12/12 h
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light/dark cycle (lights on 7 p.m.) with constant room tem-
perature (22 ± 2◦C) and humidity (60%). The experimental
protocols were approved by the local Animal Care Committee
at the Department of Biomedical Sciences, University of Cagliari,
Italy.
Adult male albino Sprague Dawley rats weighting 220–240 g at
the beginning of the experiment (8 weeks old) were purchased
from Charles River (Germany) and housed individually at the
Animal Facility of the Department of Pharmacology, Masaryk
University in Brno, Czech Republic. Animals were maintained on
a reversed 12/12 h light/dark cycle (lights on 5 p.m.) with constant
relative humidity of 50–60% and temperature of 23 ± 1◦C, and
food and water available ad-libitum. The experimental protocols
were approved by the Animal Care Committee of the Faculty of
Medicine, Masaryk University, Czech Republic.
All experiments were carried out in strict accordance with the
E.C. Regulations for Animal Use in Research (CEE No. 86/609)
and local acts.
DRUGS AND TREATMENTS
For self-administration training, WIN55-212,2 (R-[2,3-dihydro-
5-methyl-3-[(morpholinyl) methyl]-pyrrolo[1,2,3-de]-1,4-
benzoxazinyl]-(1-naphthalenyl)-methanone mesylate), (WIN,
RBI, USA) was freshly dissolved in one drop of Tween 80, diluted
in heparinized (1%) saline solution and made available at the
dose of 12.5μg/kg/infusion (volume of infusion: 100μl), as
previously described (Fattore et al., 2001). To ensure sterility,
fresh drug solutions were filtered by 0.22μm syringe filters prior
to use. For microdialysis testing, WIN solution was prepared
as described above and administered intravenously at the dose
of 0.3mg/kg (volume of injection: 1ml/kg). This drug dose
was selected on the basis of the daily amount of WIN typically
self-administered by male Lister Hooded rats under the same
experimental conditions (Deiana et al., 2007; Fattore et al., 2007;
Spano et al., 2010). Importantly, this dose of WIN was also shown
to significantly increase DA release in the shell part of the NAc of
rats (Tanda et al., 1997).
Methamphetamine (METH, Sigma Chemical Co., St Louis,
MO, USA) was dissolved in saline sterile solution and made
available at dose of 0.08mg/infusion as previously described
(Vinklerova et al., 2002).
CGS-12066B, 7-trifluoromethyl-4(4-methyl-1-piperazinyl)-
pyrrolo[1,2-a]-quinoxaline dimaleate (CGS, R&D systems,
Abingdon, Oxon, UK) was dissolved in saline and administered
intraperitoneally (i.p.) at doses ranging from 2.5 to 15mg/kg
(volume of injection: 2ml/kg), and administered 20min before
starting the session. These drug doses were selected on the basis
of their ability to acutely reduce self-administration behavior
in rats in a dose-dependent manner (Parsons et al., 1996).
Treatments were assigned on the basis of a Latin square design
whereby at least three training sessions separated two consecutive
testing sessions to allow for assessment of carryover effects. Each
animal was tested once with each drug dose and once with saline
in a counterbalanced manner, i.e., the order of presentation of
different treatments was varied between animals.
All antibiotics and anesthetics were purchased as sterile solu-
tions from local distributors.
OLFACTORY BULBECTOMY (OBX) SURGERY
At the beginning of the behavioral and neurochemical
experiments, rats were randomly divided into two groups:
OBX and SHAM rats. The bilateral ablation of the olfactory
bulbs was performed as previously described (Kucerova et al.,
2012). Animals were anaesthetized with isofluran 2% (Italy) or
i.p. injections of 50mg/kg ketamine plus 8mg/kg xylazine (Czech
Republic). The top of the skull was shaved and swabbed with an
antiseptic solution. Then, midline frontal incision was made on
the skull and the skin was retracted bilaterally. Two burr holes,
2mm in diameter, were drilled in the frontal bone 7 and 7.5mm
anterior from the bregma, 1.5 and 2mm lateral to bregma suture
for rats weighing 230 ± 10 g and 260 ± 10 g, respectively. Both
olfactory bulbs were removed by aspiration paying particular
attention to not damage the frontal cortex. Prevention of blood
loss from the ablation cavity was achieved by filling the dead
space with a hemostatic sponge. The skin above the lesion was
closed with suture. Finally, bacitracin plus neomycin powder was
applied to prevent bacterial infection. SHAM rats underwent
identical anesthetic and drilling procedures but their bulbs were
left intact.
A period of at least 20 days was allowed for the recovery from
the surgical procedure and the development of the depressive-
like syndrome. During this period, animals were handled daily
for few minutes to eliminate aggressiveness, which could other-
wise arise (Leonard and Tuite, 1981; Song and Leonard, 2005).
Before starting either drug self-administration training or micro-
dialysis experiments, animals were tested in the sucrose preference
and motor activity test for anhedonia and hyperactive locomo-
tor response to a novel environment, respectively, (Song and
Leonard, 2005).
SUCROSE PREFERENCE TEST
After 20 days of recovery from the OBX surgery, Lister-Hooded
animals were transferred into single housing with free access
to food. A two-bottle choice procedure was used to determine
baseline sucrose intake. During the 24-h training phase, all rats
were provided in their home cage with two water bottles on
the extreme sides of the cage to adapt for drinking from two
bottles. After training, one bottle was randomly switched to con-
tain 2% sucrose solution, a concentration known to provide a
robust sucrose preference (Muscat and Willner, 1989). The side
of sucrose presentation in the home cage was counterbalanced
across rats. At 4 and 24 h time intervals both bottles were removed
and the amount of liquid remaining in each bottle was mea-
sured. After 4 h, the relative position of the bottles was inverted,
i.e., they were switched from one side of the cage to the other
to avoid perseveration effects. The sucrose preference score was
calculated as the percentage of sucrose solution ingested relative
to the total amount of liquid consumed as determined before
and after each test, i.e., sucrose preference = sucrose intake/total
liquid (sucrose + water) intake × 100.
LOCOMOTOR ACTIVITY TEST
A day after conclusion of the sucrose preference test, the valid-
ity of OBX lesions was further confirmed by assessing increased
activity in a brightly lit novel environment. Rats were individually
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tested for locomotor activity using the Digiscan Animal Activity
Analyser (Omnitech Electronics, USA) as previously described
(Castelli et al., 2013). Each operant cage (42 × 30× 60 cm) was
equipped with two sets of 16 photocells located at right angles
to each other projecting horizontal infrared beams 2.5 cm apart
and 2 cm above the cage floor. The outside of the four walls
was covered with aluminium foil and two 90-W light bulbs were
located at diagonally opposed corners to provide bright illumina-
tion. Rats were brought into the testing room individually, placed
in the center of the box, and allowed to move freely for 10min.
Locomotor activity was defined from measurement of sequen-
tial infrared beam breaks recorded at every 5min after placing
the animals individually in the cage. During the 10-min test the
following behavioral parameters were measured:
- Horizontal activity: The total number of beam interruptions
that occurred in the horizontal sensors;
- Vertical activity: The total number of beam interruptions that
occurred in the vertical sensors; that is the number of times the
animal rose onto its hind legs with the front limbs either against
the wall or freely in the air (number of rearing episodes);
- Total distance (cm): The horizontal distance travelled by the
animal (dependent on animal’s trajectory).
At the end of the session, animals were gently removed from
the Plexiglas boxes and returned to their home cage. Boxes were
wiped with H2O2 between sessions to prevent olfactory cues.
INTRAVENOUS DRUG SELF-ADMINISTRATION SURGERY
At the end of the motility test, OBX and SHAM animals were
deeply anesthetized with isofluran 2% (in Italy) or i.p. injec-
tions of 50mg/kg ketamine plus 8mg/kg xylazine (in the Czech
Republic). Under aseptic conditions, a permanent intracardiac
silastic catheter was implanted through the external jugular vein
to the right atrium. The outer part of the catheter exited the skin
in the midscapular area. After surgery, each animal was allowed
for recovery, individually, in its home cage with food and water
freely available. On the following 6–7 days, each rat received an
intravenous infusion of gentamicin (0.16mg/kg, Italy) or hep-
arinized cephazoline (Vulmizolin 1.0 g, Czech Republic) solution
followed by 0.1ml of a heparinized (1%) sterile saline solution
to prevent infection and occlusion of the catheter. During recov-
ery, changes in general behavior and body weight weremonitored.
When a catheter was found to be blocked or damaged, the animal
was excluded from the analysis. Once completely recovered from
surgery, food-restriction condition was applied, where rats were
fed with 20 g/day of standard rat chow given in the home cage
immediately after each session.
INTRAVENOUS SELF-ADMINISTRATION
WIN55-212,2 self-administration was conducted in 12 oper-
ant chambers (29.5 × 32.5 × 23.5 cm, Med Associates, Vermont,
USA) using lever-pressing as operandum under a continuous
(FR-1) schedule of reinforcement, i.e., each active response was
reinforced. Each chamber was encased in a sound and light atten-
uating cube. In addition, chambers had a ventilation fan, and
a front panel equipped with two retractable levers (each 4 cm
wide) positioned 12 cm apart, 8 cm from the grid and extend-
ing 1.5 cm into the box. A white stimulus light was placed
above each lever and a red house light was located on the
opposite wall. Intravenous infusions of WIN were delivered by
a software-operated infusion pump (Med Associates, Vermont,
USA) through a counterbalanced single-channel swivel and an
extra length of plastic tubing enclosed in a metal spring connect-
ing the swivel to the catheter fitting on the animal’s back. Pressure
on the lever, defined as active, resulted in: (i) extinction of the
house light and illumination of the stimulus light above the active
lever for 15 s; (ii) retraction of both levers; and (iii) activation of
the infusion pump for 5.8 s delivering 0.1ml intravenous infu-
sion of drug solution. On completion of the 15 s timeout period,
levers were re-extended into the chamber, stimulus light went out
and the house light was switched on. Pressure on the other lever,
defined as inactive, was not coupled to any successive event, but
was always recorded to provide an index of basal activity levels.
Assessment of schedules and data collections was programmed
by means of a computer using the MED Associates MED-PC
software package. Throughout each phase of the study, locomo-
tor activity was monitored within the operant chambers, which
were equipped with a series of photocells located 3.5 cm above the
cage floor. The number of photocell beam breaks was recorded
and served as a measure of general horizontal locomotor activ-
ity. Self-administration sessions lasted 120min and took place 7
days/week between 9 a.m. and 1 p.m. during the dark period of
the cycle.
Acquisition training was carried out until steady baseline of
drug intake was reached. Response was considered stable when
animals displayed accurate discrimination between the active and
inactive lever. Acquisition was defined as the number of active
lever-presses >15 and not differing by more than 20% for three
consecutive days. Rats not meeting the acquisition criterion were
excluded from the subsequent phases of the study. Only rats
developing a stable pattern of WIN intake were allowed to con-
tinue daily self-administration sessions until day 30. Then, extinc-
tion condition was introduced by replacing WIN with sterile
vehicle solution (1% Tween 80 in saline solution) which allowed
responses to be recorded without drug consequences. All other
experimental parameters were left unchanged; therefore pressure
on the active lever resulted in an infusion of 0.1ml of vehicle
accompanied by the presentation of the stimulus light previously
paired with WIN delivery. Drug-reinforced behavior was consid-
ered extinguished when the maximum number of responses on
the active lever was ≤10 and the total number of lever presses
(i.e., active + inactive) in a single test session was ≤20.
Methamphetamine self-administration was conducted as pre-
viously described (Kucerova et al., 2009, 2012) in 10 standard
experimental (30 × 25× 30 cm, Coulbourn Instruments, USA)
boxes using nose-poking as operandum under a final FR-2 sched-
ule of reinforcement, i.e., animal had to make two consecutive
nose-pokes on the active hole to obtain a single drug infusion.
Each cage was provided with two nose-poke holes allocated on
one side and programmed by software Graphic State Notation
3.03 (Coulbourn Instruments, USA). Specifically, training ses-
sions were initially conducted under a FR-1 schedule of reinforce-
ment. Fixed-ratio requirement was then raised to FR-2 when the
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animal fulfilled the following conditions for three consecutive ses-
sions: (a) at least 70% preference of the drug-active nose-poke,
(b) minimum intake of 10 infusions per session, or (c) stable
intake of the drug (maximum 10% deviation). Nose-pokes in the
active hole led to the activation of the infusion pump and admin-
istration of a single infusion followed by a 10 s timeout, while
nose-pokes in the inactive hole were recorded but not rewarded
and reset the count of active nose pokes back to zero. The cage
was illuminated by a house light during the session. The light was
flashing when administering infusion and off during the time-
out period. Self-administration sessions lasted 90min and took
place 7 days/week between 7 a.m. and 2 p.m. during the dark
period of the cycle. Acquisition criteria were the same as for WIN
self-administration behavior.
In both apparatuses, assignment of the active (drug-paired)
and the inactive (not drug-paired) levers/holes was counter-
balanced between rats and remained constant for each subject
throughout all the experiments. CGS testing was performed on
Lister Hooded and Sprague Dawley rats self-administering WIN
and METH, respectively, during the maintenance phase of the
self-administration training, i.e., once animals stabilized their
drug intake.
MICRODIALYSIS SURGERY AND PROCEDURE
A separate batch of drug-naïve Lister Hooded male rats was
used for the in vivo microdialysis study. Rats were anesthetized
with 2% isoflurane and placed in a stereotaxic frame (David
Kopf Instruments, Tujunga, CA, USA). The skull was exposed
and a small hole was drilled on the right side. A concentric
self-made microdialysis probe with a 2mm dialyzing surface
length (AN 69AF; Hospal-Dasco, Bologna, Italy; cut-off 40,000
Da, in vitro recovery about 30%) was inserted vertically into the
shell of the NAc (coordinates from bregma, AP: +1.7, L: ±0.7,
V: −8.2) according to the Paxinos anatomical atlas (Paxinos
and Watson, 1998) and then fixed to the skull using den-
tal acrylic cement. During the same surgery session, rats were
implanted with intravenous catheters as previously described,
which allowed intravenous administration of WIN. Starting 24 h
from implantation of the dialysis probe, artificial cerebrospinal
fluid (147mM NaCl, 4mM KCl, 1.5mM CaCl2, pH 6–6.5) was
pumped through the dialysis membrane at a constant rate of
2.5μL/min with a CMA/100 microinjection pump (Carnegie
Medicine, Sweden). Dialysate samples (50μL) were collected
every 20min and directly injected into a high performance
liquid chromatography system in order to quantify DA. The
system consisted of an isocratic pump (ESA model 580; ESA,
Chelmsford,Massachusetts), a 7125 Rheodyne injector connected
to a Hewlett Packard (Waldbronn, Germany) series 1100 col-
umn thermostat with a reverse phase column (LC18 DBSupelco,
5μm, 4.6 × 150mm), and an ESA Coulochem II detector. The
first electrode of the detector analytical cell was set at 400mV
and the second at −180mV; column temperature was set at
30◦C. The mobile phase, delivered at 1.0mL/min, consisted of
50mM/L sodium acetate, 0.073mM/L Na2 ethylenediaminete-
traacetic acid, 0.35mM/L 1-octanesulfonic acid, 12% methanol,
pH 4.21, with acetic acid. In this condition the sensitivity of
the assay for DA was 2 fM/sample. Only results deriving from
rats with correctly positioned dialysis probes were included in
statistical analysis of data. The location of the probe was deter-
mined histologically at the end of each experiment by examining
coronal brain sections (50μm) stained with cresyl violet.
STATISTICAL DATA ANALYSIS
At the end of the study, rats were anesthetized by isofluran inhala-
tion and decapitated. Their brains were removed for confirmation
of the ablation of the olfactory bulbs. Only rats with a complete
removal of both olfactory bulbs with no damages to the frontal
cortex were included for data analysis.
Primary data were summarized using arithmetic mean and
standard error of the mean estimate. Statistical analysis of dif-
ferences between OBX and SHAM rats in time-related differ-
ences used One-Way and Two-Way analysis of variance (ANOVA)
with repeated measures model. In Two-Way repeated measures
ANOVA, the group of rats was entered as the between-group
factor and the time-points as repeated within-subject measure.
One-Way ANOVA was used when comparing the time-points
within given experimental group of rats.
Time-related changes and differences between OBX and
SHAM groups during drug self-administration after acute pre-
treatment with the 5-HT1B receptor agonist CGS-12066B were
analyzed using Two-Way repeated measures ANOVA.
Microdialysis data were analyzed using One-Way or Two-Way
ANOVA (treatment × time), followed by Tukey’s or Bonferroni’s
post-hoc test comparison procedures, respectively. The level of
statistical significance was set at p < 0.05.
Statistics were calculated using the statistical package SPSS
(version 2.0).
RESULTS
BEHAVIORAL PROFILE AFTER OBX SURGERY (LISTER HOODED RATS)
To verify the development of a depressive-like phenotype in OBX
lesioned animals, basal behavioral differences between SHAM
and OBX rats were established by measuring sucrose preference
and locomotor activity. Anhedonia and hyperactive response to a
novel brightly lit environment are two major features of OBX rats
consistently described by previous studies (Kelly et al., 1997; Song
and Leonard, 2005; Romeas et al., 2009).
As shown in Figure 1, OBX rats consumed significantly lower
proportion of sucrose than SHAM rats (p < 0.001) after both 4
and 24 h from sucrose solution presentation, which confirmed
a reduced hedonic response as a consequence of ablation of the
olfactory bulbs. Differences between the two dependent variables
were tested using independent Student t-test.
Figure 2 illustrates results from the motor activity test con-
ducted in brightly lit conditions. In all locomotor measures (i.e.,
horizontal activity, vertical activity, and total distance travelled),
statistically significant differences were detected at 5min of mea-
surement, a time-point representing response to novel environ-
ment (horizontal activity, p < 0.001; vertical activity, p < 0.05;
total distance travelled, p < 0.01). At the 10min time-point (lit-
tle effect of novelty), a significant difference was only present
in vertical activity measure (p = 0.032). Differences between the
two independent variables were tested using independent Student
t-test.
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FIGURE 1 | OBX rats display anhedonia. The sucrose preference test in
SHAM (n = 6) and OBX (n = 7) Lister Hooded rats. Data are percentages
(±s.e.m.) of sucrose solution consumed at two time-points, i.e., after 4 and
24 h from the beginning of the test. Student t-test, ∗∗∗p < 0.001.
WIN 55-212,2 SELF-ADMINISTRATION IN LISTER HOODED RATS
Figure 3A shows responses of SHAM and OBX rats on the active
lever during the acquisition phase of WIN self-administration
training. Repeated measures ANOVA revealed no significant
effects over the first 8 days of training, whereas from day 9 onward
a significantly higher active lever-pressing rate was observed in
OBX compared with SHAM rats (repeated measures ANOVA:
α < 0.001). In contrast, inactive lever-pressing rates of OBX and
SHAM rats were statistically indistinguishable throughout the
30 days of training and remained constantly below 6 responses
per session starting from the first week of training, with the
sole exception of the initial 4 days of training (data available as
Supplementary Figure 1A). This indicates that the increase in
the rate of responding observed in OBX rats was not due to an
unspecific effect, as further confirmed by the finding of no signif-
icant differences between OBX and SHAM animals in the basal
motor activity during the self-administration daily sessions, as
measured by the mean number of interruptions of the photocell
beams located inside the boxes (mean activity over the mainte-
nance phase: 989 ± 41 and 1005 ± 27 for OBX and SHAM rats,
respectively).
In accordance with this, the total amount of WIN consumed
by OBX rats during the maintenance phase, i.e., once animals
stabilized drug intake, was significantly higher than that con-
sumed by SHAM rats. More specifically, meanWIN intake during
the last 7 days of training before extinction was significantly
higher (+105%) in OBX than in SHAM rats (repeated mea-
sures ANOVA: α < 0.001) (Figure 3B). However, the percentages
of rats meeting acquisition criteria for WIN self-administration
in OBX and SHAM groups were similar, being 85.5 and 86.8%,
respectively.
Furthermore, OBX and SHAM rats displayed clear cut differ-
ences in the time course of operant behavior even when saline was
substituted for WIN, i.e., during extinction training (Figure 3C).
Analysis of response on the active lever by repeated measures
ANOVA showed significant differences between OBX and SHAM
animals (α = 0.012 from day 1 to 7; α = 0.004 from day 8 to
FIGURE 2 | OBX rats display hyperactivity in a novel aversive
environment. Spontaneous horizontal and vertical activity, expressed as
mean counts of photobeam interruptions, and total distance travelled (in
centimeters) in SHAM (n = 6) and OBX (n = 7) Lister Hooded rats. Data are
shown as means (±s.e.m.) at two time-points (5 and 10min of
measurement). Student t-test, ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
14, α < 0.001 from day 15 to 28). Specifically, on the 1st day
of extinction, OBX and SHAM rats reacted to saline substi-
tution by increasing their mean active responding from 39 to
78.5 and from 16.86 to 45.17, respectively, which corresponds to
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FIGURE 3 | Cannabinoid self-administration training in OBX and SHAM
rats. Data are shown as means (±s.e.m.). (A) Acquisition phase: mean
active lever presses in SHAM (n = 6) and OBX (n = 7) Lister Hooded rats
during WIN55,212-2 self-administration. ∗∗∗α < 0.001, repeated measures
ANOVA. (B) Maintenance phase: mean WIN intake over the last seven
training sessions in SHAM (n = 6) and OBX (n = 7) Lister Hooded rats
during WIN self-administration. ∗∗∗α < 0.001, repeated measures ANOVA.
(C) Extinction phase: mean active lever presses in SHAM (n = 6) and OBX
(n = 7) Lister Hooded rats during extinction of WIN self-administration.
∗α < 0.05, ∗∗α < 0.01, and ∗∗∗α < 0.001, repeated measures ANOVA.
+101 and +168% with respect to the last (30th) day of WIN
self-administration training. Following 1-week extinction, OBX
and SHAM rats reduced their active responding of −41 and
−65%, respectively, with respect to day 1 extinction. Differences
between OBX and SHAM groups in the responding on the active
lever slightly reduced after 2 and 3 weeks of extinction training
(OBX: −65 and −79%, SHAM: −78 and −90%, respectively).
Finally, response latency (defined as time elapsed from com-
mencement of the experimental session until the first active lever
press) was significantly different between the two groups. More
specifically, response latency was shorter in OBX than SHAM
rats from day 9 onward (repeated measures ANOVA: α = 0.029
from day 9 to 16; α < 0.001 from day 17 to 30) (Figure 4A),
which suggests that after initial exposure to the CB1 receptor
agonist the bulbectomized rats may be more motivated than con-
trol animals to obtain it. Moreover, analysis of temporal patterns
of responses revealed quantitative but not qualitative differences
between OBX and SHAM rats during self-administration training
since the response rate was typically slow and evenly distributed
throughout the 2 h test session in both groups (Figure 4B).
EFFECT OF ACUTE PRE-TREATMENT OF CGS-12066B ON DRUG
SELF-ADMINISTRATION
The effect of an acute administration of the serotonin 5-HT1B
receptor agonist CGS-12066B (CGS) was tested only after acquir-
ing reliable WIN self-administration, i.e., once rats stabilized
daily drug intake. Overall, we did not find changes in WIN self-
administration after acute pre-treatment with the CGS in Lister
Hooded OBX or SHAM rats. Figure 5 illustrates the percentage
changes of active lever presses from the baseline after an acute
challenge with CGS (2.5, 5, and 10mg/kg) and saline control
as compared to previous 6-day mean responding (i.e., base-
line). The repeated measures ANOVA with OBX/SHAM group
as cofactor did not detect a significant effect of drug treatment
within each group nor between groups. The post-hoc p-values
for each drug dose were as follows for SHAM: 2.5mg/kg: p =
0.241; 5mg/kg: p = 0.071; 10mg/kg: p = 0.128, and for OBX:
2.5mg/kg: p = 0.963; 5mg/kg: p = 0.652; 10mg/kg: p = 0.523.
It was reported that the effects of serotonergic drugs may
differ significantly depending on the animal strain and the exper-
imental conditions used (Horowitz et al., 1997; Uphouse et al.,
2002; Miryala et al., 2013), and that not all rat strains do self-
administer WIN spontaneously (Deiana et al., 2007). Moreover,
the CGS compound was found to reduce amphetamine (Fletcher
and Korth, 1999) and alcohol (Tomkins and O’Neill, 2000;
Czachowski, 2005), but not cocaine (Parsons et al., 1996), self-
administration. Thus, we decided to test the CGS compound
on the self-administration of a pharmacologically different drug,
such as METH, which is known to be strongly self-administered
byOBX rats.We therefore tested CGS inOBX and SHAMSprague
Dawley rats self-administering METH using different response-
like operandum, i.e., nose-poking instead of lever-pressing, and
a slightly higher schedule of reinforcement (FR-2). Figure 6A
illustrates responses of SHAM and OBX rats on the active hole
during the acquisition and maintenance phases of METH self-
administration. In line with previous findings (Kucerova et al.,
2009, 2012), rats stabilized METH self-administration behavior
within 14 days of training intake with a mean daily drug intake of
1.8mg in SHAM and 3mg in OBX animals (METH intake data
shown in Supplementary Figure 2). Repeated measures ANOVA
revealed no significant effects over the first 6 days of training,
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FIGURE 4 | Latency to the first active response (A) and patterns of
responding (B) in SHAM and OBX Lister Hooded rats during WIN
self-administration. (A) Latency (seconds) to the first active lever presses
in SHAM (n = 6) and OBX (n = 7) rats. Data are shown as means (±s.e.m.).
∗α < 0.05 and ∗∗∗α < 0.001, repeated measures ANOVA. (B) Quantitative,
but not qualitative, differences in the active responding patterns between
OBX and SHAM rats. Individual representative records illustrating
responding patterns of OBX (first three patterns) and SHAM (last three
patterns) rats on the active lever on the last day of the self-administration
training (day 30). Each tick denotes the time of every response on the
active lever. Cumulative numbers of active responses made over the 2 h
test sessions are illustrated on the right side of each pattern.
whereas from day 7 onward a significantly higher active nose-
poking rate was observed in OBX compared with SHAM rats
(repeated measures ANOVA: α < 0.05). However, while during
WIN self-administration the numbers of inactive lever-presses
was constantly below 5 during the maintenance phase, inac-
tive nose-pokes during METH self-administration were higher in
both OBX and SHAM rats (see Supplementary Figure 1B), an
effect likely due to the activational motor effects of METH. Yet,
the mean number of active nose-pokes was substantially higher
than the inactive ones, which supports the specificity of animal
responding for METH (preference of the active operandum dur-
ing the maintenance phase was higher than 70% in all animals).
Figure 6B reports the percentages of active nose pokes for METH
after acute pre-treatment with saline control, 10 and 15mg/kg of
CGS-12066B compared to previous 6-day mean responding (i.e.,
baseline) in SHAM and OBX Sprague Dawley rats. The repeated
measures ANOVA with OBX/SHAM group as cofactor did not
detect a significant effect of drug treatment within each group nor
between groups. The post-hoc p-values for each drug dose were
as follows for SHAM: 10mg/kg: p = 0.508; 15mg/kg: p = 0.550,
and for OBX: 10mg/kg: p = 0.232; 15mg/kg: p = 0.319. These
findings indicate that, as for WIN self-administration, acute pre-
treatment with the 5-HT1B receptor agonist did not modify the
voluntary intake of METH.
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FIGURE 5 | Acute pre-treatment with CGS does not affect WIN
self-administration. Effect of acute pre-treatment with CGS-12066B on
WIN self-administration in SHAM (n = 6) and OBX (n = 7) Lister Hooded
rats. Data are expressed as percentage changes of active lever pressing
compared to 6-day baseline (assumed as 100%). The repeated measures
ANOVA did not detect a significant effect of drug treatment.
IN VIVO MICRODIALYSIS OF DOPAMINE LEVEL IN THE NUCLEUS
ACCUMBENS SHELL OF LISTER HOODED RATS
Figure 7 shows results from microdialysis experiment aimed
at measuring the release of DA in the NAc shell of Lister
Hooded SHAM and OBX rats following an intravenous injec-
tion of 0.3mg/kg of WIN, a dose mimicking the mean amount
of drug typically self-administered by naive Lister Hooded rats
(Deiana et al., 2007; Fattore et al., 2007; Spano et al., 2010),
and known to increase DA level in the rat NAc shell (Tanda
et al., 1997). During the pre-treatment period, basal extracel-
lular values of DA in the NAc shell did not differ significantly
between the two groups (Figure 7A). As shown in Figure 7B,
after WIN administration, we found a significantly increased
(about +40%) extracellular DA level in SHAM rats compared
to their basal level during the first 40min after drug injec-
tion [One-Way ANOVA F(8, 24) = 4.997, p = 0.0010]. However,
the WIN challenge did not increase DA levels in OBX rats, in
which DA levels did not significantly differ from to their pre-
vious baseline during the 2-h measurement [One-Way ANOVA
F(8, 24) = 0.3730, p = n.s.]. Data are expressed as mean ± s.e.m.
percentage variation of basal levels. Two-Way ANOVA revealed
a significant effect of treatment × time interaction [F(8, 48) =
3.07, p = 0.0071; ∗∗p < 0.01 and ∗p < 0.05, Bonferroni post-
test].
DISCUSSION
Findings of the present study demonstrated that bulbectomized
rats: (i) do self-administer higher amount of the cannabi-
noid CB1 receptor agonist WIN55,212-2 than SHAM con-
trol rats, (ii) do not alter voluntary intake of the CB1
receptor agonist after acute pre-treatment with the sero-
tonergic 5-HT1B receptor agonist CGS12066B, and (iii) do
not increase DA level in the NAc shell in response to an
acute challenge with a dose of WIN (0.3mg/kg), as SHAM
rats do.
WIN SELF-ADMINISTRATION IN OBX AND SHAM RATS
Bulbectomized rats have been previously reported to
self-administer more nicotine (Vieyra-Reyes et al., 2008),
amphetamine (Holmes et al., 2002), and METH (Kucerova et al.,
2012) than SHAM control rats. Yet, despite clinical evidence
for a significant association between smoking cannabis and
major depression (Horwood et al., 2012; Lev-Ran et al., 2013),
cannabimimetic drug-taking behavior was never investigated
in an animal model of depression. Cannabinoid CB1 receptor
agonists were shown to be readily self-administered by mice,
rats, and monkeys (Martellotta et al., 1998; Fattore et al., 2001;
Justinova et al., 2003). Notably, rate of responses was critically
dependent on a variety of experimental conditions including
drug unitary dose (Martellotta et al., 1998), food restriction
regimen (Fattore et al., 2001), and type of operandum (Deiana
et al., 2007). In this study, we adopted all parameters and
experimental conditions that support a robust cannabinoid
drug-taking behavior in the Lister Hooded rat strain (Deiana
et al., 2007).
Before starting self-administration training and microdialy-
sis experiments, we verified the development of a depressive-like
phenotype in OBX lesioned animals by assessing the presence of
anhedonia and hyperactive locomotor response to novel environ-
ment, which are two of the major hallmarks of this animal model
of depression (Kelly et al., 1997; Song and Leonard, 2005; Romeas
et al., 2009).
WIN self-administration by OBX rats significantly differed
from SHAM controls as OBX animals showed higher rates of
drug-associated operant responses during themaintenance phase,
i.e., after initial acquisition. Indeed, although both OBX and
SHAM rats needed a similar number of training sessions to
acquire self-administration behavior, rates of active lever-pressing
during the maintenance sessions were remarkably higher in OBX
than SHAM rats. Therefore, the amount of WIN consumed by
OBX rats over the 30 test sessions resulted significantly higher
than in SHAM rats (mean cumulative amount of WIN over the
30-day training: 12.71 vs. 7.9mg for OBX and SHAM, respec-
tively). Similar rates of acquisition indicate that OBX rats required
the same time of SHAM rats to stabilize their drug intake and
suggest that development of a depressive-like phenotype is not
associated with learning or memory deficits able to affect the
acquisition of the operant task, although OBX animals have been
reported to display impaired spatial learning (Song and Leonard,
2005). On the other hand, higher drug intake in OBX rats during
the maintenance phase suggests that bulbectomized animals are
differently responsive than SHAM controls to the cannabinoid,
which might lend some support to the proposed self-medication
theory of smoking cannabis to alleviate symptoms of depression
(Gruber et al., 1996; Ogborne et al., 2000).
Our results are in line with the notion that OBX rats differ
in the behavioral responses to acute and repeated exposure to
other addictive drugs including METH (Kucerova et al., 2012),
alcohol (Chiang et al., 2008), nicotine (Vieyra-Reyes et al., 2008),
cocaine (Calcagnetti et al., 1996; Chambers et al., 2004), and
amphetamine (Holmes et al., 2002). Notably, enhanced WIN
intake by OBX rats recorded in this study was unlikely due to
changes in locomotor activity since motor activity during the
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FIGURE 6 | Acute pre-treatment with CGS does not affect METH
self-administration. (A)METH self-administration in OBX and SHAM rats.
Data expressed as daily means (±s.e.m.) of active nose-pokes in SHAM (n = 7)
and OBX (n = 7) Sprague Dawley rats during methamphetamine
self-administration training. Significant difference was recorded from the day 7
onwards, ∗α < 0.05 (day 7–12: ∗α = 0.041, day 13–18: ∗α = 0.027, repeated
measures ANOVA). (B) Effect of acute pre-treatment with CGS-12066B on
METH self-administration. Data are expressed as percentage changes of active
lever pressing compared to six-day baseline (assumed as 100%). The repeated
measures ANOVA did not detect a significant effect of drug treatment.
daily training session was not dissimilar between OBX and SHAM
animals as confirmed by their similar numbers of photocell beams
breaks measured within the operant boxes during daily training
sessions.
Differences in the response rates on the active lever were also
observed when vehicle was substituted for the CB1 receptor ago-
nist. In fact, rates of responses in OBX rats were consistently
higher than in SHAM rats not only when WIN was contin-
gently available but also when it was absent, as during extinction
training. A neurobiological mechanism that may contribute to
the resilience of OBX rats to extinguish not-rewarded operant
responses is a dysfunction of the front-cortical neuronal circuits
critically involved in the inhibition of on-going activity upon
withdrawal of the reinforcers (Jentsch and Taylor, 1999). This
hypothesis is corroborated by the finding that OBX animals (i)
are unable to adapt to environmental changes and show hypere-
motional responses (Van Riezen and Leonard, 1990), (ii) exhibit
impulsive-like traits (Kamei et al., 2007), and (iii) display signif-
icant increases in both CB1 receptor density and functionality in
the prefrontal cortex (Rodriguez-Gaztelumendi et al., 2009).
EFFECT OF 5-HT1B RECEPTOR ACUTE STIMULATION ON DRUG
SELF-ADMINISTRATION
In an attempt to evaluate possible mechanisms underlying the
observed differences in WIN self-administration between OBX
and SHAM rats, we tested the effect of a serotonin 5-HT1B
receptor agonist on the cannabinoid agonist intake. This choice
was based on the finding that cortical and hippocampal 5-HT1B
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FIGURE 7 | OBX rats do not show enhanced dopamine level following
acute WIN challenge. (A) Basal extracellular levels (fmol/μl of dialysate,
mean ±s.e.m.) of DA in the NAc shell of SHAM (n = 4) and OBX (n = 4)
Lister Hooded rats. No significant difference was found between the two
groups (One-Way ANOVA, p = 0.45). (B) Effect of an intravenous
administration of WIN 0.3mg/kg on DA release in the nucleus accumbens
shell of SHAM (n = 4) and OBX (n = 4) Lister Hooded rats. ∗p < 0.05 and
∗p < 0.01, Two-Way ANOVA followed by Bonferroni’s post-hoc test.
receptors are critically involved in ethanol dependence and that
their activation in limbic areas may attenuate amphetamine
self-administration (Miszkiel et al., 2012). Moreover, a hypo-
functionality of 5-HT1B receptors was observed in depressed
patients (Murrough et al., 2011), and a polymorphism at the 5-
HT1B receptor gene was found to be associated with alcoholism
(Lappalainen et al., 1998). The 5-HT1B receptor agonist CGS-
12066B was shown to selectively decrease operant responses for
ethanol (Czachowski, 2005). This compound is a full agonist with
high selectivity to the 5-HT1B receptor (Neale et al., 1987) and,
to minor extend, to the 5-HT1A receptors. The range of doses
of the 5-HT1B receptor agonist CGS-12066B used in this study
was shown to be effective in acute in altering aggressive (De Boer
and Koolhaas, 2005) and sexual behavior (Maciag et al., 2006) as
well as some reward-related behaviors, such as DA-mediated rein-
forcement (Parsons et al., 1996). However, it did not affect cocaine
self-administration in rats (Parsons et al., 1996), similarly to our
findings on WIN self-administration.
Importantly, both the effects of serotonergic drugs (Horowitz
et al., 1997; Uphouse et al., 2002; Miryala et al., 2013) and
WIN self-administration behavior (Deiana et al., 2007) have
been reported to greatly vary depending on rat strain and/or
experimental parameters and procedures adopted. Moreover, the
CGS compound was found to affect drug self-administration
selectively, as it decreases alcohol (Grant et al., 1997; Maurel
et al., 1999; Tomkins and O’Neill, 2000; Czachowski, 2005) and
d-amphetamine (Fletcher and Korth, 1999), but not cocaine
(Parsons et al., 1996) intake. Thus, we decided to test CGS-
12066B on the self-administration of METH for which OBX rats
are known to display higher responding level than SHAM rats
(Kucerova et al., 2012), as for WIN. Yet, acute pre-treatment with
the 5-HT1B receptor agonist CGS-12066B did not significantly
alter the intake of METH neither in OBX and SHAM Sprague
Dawley rats nor in intact Wistar rats as recorded in our earlier
unpublished pilot experiment (data available as Supplementary
Figure 3).
Thus, the present findings indicate that WIN and METH, like
cocaine (Parsons et al., 1996) self-administration, are not affected
by acute stimulation of the 5-HT1B receptor. Serotonin 5-HT1B
receptors are expressed throughout the brain of rodents. They
are located in the axon terminals of both 5-HTergic and non-5-
HTergic neurons where they act as inhibitory autoreceptors or
heteroreceptors, respectively, (Barnes and Sharp, 1999; Moret and
Briley, 2000; Pytliak et al., 2011; Cai et al., 2013), and have been
difficult to study because of the diversity of their localization and
the absence of highly selective receptor antagonists. Findings from
the present study do not allow excluding the possibility that a
chronic rather than an acute stimulation of 5-HT1B receptors
might alter WIN and METH self-administration. Thus, future
studies will evaluate the effects of chronic stimulation of 5-HT1B
receptor by CGS-12066B, administered systemically or locally, on
WIN and METH self-administrations.
REDUCED SENSITIVITY OF OBX RATS TO THE WIN STIMULATION
EFFECT ON DOPAMINE RELEASE IN THE NUCLEUS ACCUMBENS SHELL
Enhanced drug self-administration can be linked to a dysfunc-
tion in the reward system, which is very likely to occur in OBX
animals given the chemical and molecular changes that bulbec-
tomy induces in several neurotransmitter systems, including the
dopaminergic one (Masini et al., 2004; Sato et al., 2010), a major
component of the brain reward system.
In intact animals, acute administration of WIN55,212-2 is
known to increase extracellular DA levels in the NAc of freely
moving rats (Gardner and Lowinson, 1991; Cheer et al., 2004;
Polissidis et al., 2013). Moreover, DA content in the rat NAc shell
was shown to increase appreciably in respect to basal values dur-
ing WIN self-administration (Fadda et al., 2006). According to
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this, the SHAM rats in this study significantly increased accumbal
DA levels in response to an intravenous administration of a dose
of WIN, 0.3mg/kg, very similar to that daily self-administered by
rats. Notably, the same dose of WIN enhances DA levels in the
NAc shell of drug-naïve Sprague Dawley rats (Tanda et al., 1997).
However, in our experiment WIN did not enhance DA levels in
bulbectomized rats.
To explain this finding it could be of help to consider the
multiple dysregulations that OBX induce in the endocannabinoid
brain system. Cannabinoid CB1 receptor density is significantly
increased in OBX rats in themedial prefrontal cortex (mPFC) and
amygdala while it does not change in the caudate-putamen, hip-
pocampus, and dorsal raphe nucleus (Rodriguez-Gaztelumendi
et al., 2009). CB1 receptor function is significantly enhanced in
the mPFC of OBX animals with respect to SHAM controls, but
not in other brain regions with the exception of a slight, not
significant, increase in the amygdala (Rodriguez-Gaztelumendi
et al., 2009). Moreover, OBX does not affect DA D1- and D2-
like receptors in the NAc (Sato et al., 2010). Thus, potential
changes in the number or function of either the CB1 or the
dopaminergic receptors following OBX are unlikely to account
for the absence of WIN-induced effect on DA release in the
NAc of OBX rats. On the other hand, there is no clear evidence
that DA release in the reward pathway depends on DA recep-
tors. Instead, it is known that midbrain DA neurons produce
endocannabinoids which retrogradely influence the glutamate
and GABA projections and thus regulate the inhibitory and
excitatory inputs to the reward circuit (Melis and Pistis, 2007).
Glutamatergic and GABAergic systems are both dysregulated in
the OBX model leading, among others, to a hyperactive response
to novel environment (Song and Leonard, 2005). These dys-
regulations may contribute to the differential reactivity of the
mesolimbic dopaminergic system in OBX rats. Thus, future stud-
ies will be performed to assess whether chronic treatment with
this dose of WIN (0.3mg/kg) as well as acute challenges with
higher WIN doses may elicit an increase in DA levels in the
NAc shell of OBX rats, and to evaluate CB1 and DA receptor
densities.
To summarize, this study demonstrated that OBX rats self-
administer more cannabinoid agonist than SHAM control rats,
and that WIN taking behavior is not significantly affected by
acute stimulation of 5-HT1B receptors. The close anatomical and
functional association between the olfactory bulbs and the lim-
bic system may help to understand why OBX rats differ from
SHAM rats in drug self-administration behavior. The neurons of
the olfactory bulbs are widely interconnected with other brain
regions including cortical areas and limbic nuclei (Song and
Leonard, 2005). The projections to these nuclei may be par-
ticularly relevant to changes in emotional and reward-related
behavior in bulbectomized rats. Removal of the olfactory bulbs
may alter, if not disrupt, the activity in brain circuits, particularly
those influencing the dopaminergic system which is critical for
processing drug taking and seeking behaviors. As OBX rats, con-
trary to SHAM, did not display a significant increase of DA levels
in the NAc shell after an acute WIN challenge, we hypothesize
that a depressive-like state may alter the rewarding effects of the
drugs.
In conclusion, our findings showed that OBX markedly affects
self-administration of cannabinoid CB1 receptor agonist, possi-
bly through a reduction of its rewarding effects to which ani-
mals compensate by increasing WIN intake. A decreased DA
neurotransmission in the NAc shell might contribute to this
compensatory behavior. Thus, a follow-up study will evaluate (i)
a dose-response effect of acute and chronic WIN and METH
administration on NAc shell DA levels in OBX and SHAM rats,
and (ii) DA levels after immediate (24 h), short-term (1 and 2
weeks), and long-term (4-weeks) cessation from chronic drug
exposure. Future studies will also evaluate whether OBX and
SHAM rats also differ in the reinstatement of cannabinoid-
seeking behavior trigger by drug, cue, or stress primings.
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